Rhythm Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
222 Berkeley St Fl 12, Boston, Massachus...Phone Number
(857) 264-4280Website
www.rhythmtx.comRevenue
$217.2 MillionStock Symbol
RYTMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
4
1
1
1
1
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical research and development company focused on developing precision medicines for rare genetic obesity disorders. The company specializes in treatments targeting the melanocortin-4 receptor pathway diseases that cause hyperphagia and severe obesity. Founded in 2008, Rhythm Pharmaceuticals conducts scientific research to address the root causes of these rare conditions, advancing therapeutic solutions for patients with these specific genetic disorders. The company operates internationally with presence in North America and Europe, including France and the Netherlands.Explore more
Rhythm Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
AH
Senior Director, Organizational Effectiveness...
MW
People Operations Senior Director, Total Rewa...
TS
Senior Director, Human Resources & Business P...
TM
Director, Field Development
HT
Director, Human Resources, International (Jap...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rhythm Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Rhythm Pharmaceuticals launches new products
Earning: See what the market has to say on Rhythm Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Rhythm Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Rhythm Pharmaceuticals
Click to see if Rhythm Pharmaceuticals had a recent Job posting/layoffs
Rhythm Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Rhythm Pharmaceuticals has new funding data
Check out if Rhythm Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Rhythm Pharmaceuticals
Find more new buyers
Compare Similar Companies to Rhythm Pharmaceuticals
Compare insights from companies similar to Rhythm Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$23.9M
51-200
Private
$126.7M
2001
SB
Sofia BlehautAssociate Director and Regional Clinical Operations Manager
Company Profile Activity
Activity Insights
Rhythm Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rhythm Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals financials insights
Gather financial insights about Rhythm Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$40M
2012
Series B
$33M
2017
Other Financing Round
$41M
Stock Offering
$138M
2018
Stock Offering
$174M
2019
Stock Offering
$172.5M
2022
Debt
$100M
2024
Series A
$150M
Rhythm Pharmaceuticals Tech Stack
A closer look at the technologies used by Rhythm Pharmaceuticals
Most Recent Scoops
Hiring Plans
Rhythm Pharmaceuticals has more open roles in Marketing than it has had at any time in the past 6 months.
Hiring Plans
Hiring Plans
Rhythm Pharmaceuticals has more open roles in Sales than it has had at any time in the past 6 months. Areas of expertise include: Pharmaceutical Sales.
Hiring Plans
Hiring Plans
Rhythm Pharmaceuticals has more open roles in Finance than it has had at any time in the past 6 months. Areas of expertise include: Process Design, Cash Flow Forecasting, Project Management, Scenario Analysis, Banking Administration, Data Manipulation, and Financial Integration.
Hiring Plans
Open Position
Open Position
Rhythm Pharmaceuticals News & Media
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) with acquired HO at one year --Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company’s Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Rhythm Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Rhythm Pharmaceuticals is a biopharmaceutical research and development company focused on developing precision medicines for rare genetic obesity disorders. The company specializes in treatments targeting the melanocortin-4 receptor pathway diseases that cause hyperphagia and severe obesity. Founded in 2008, Rhythm Pharmaceuticals conducts scientif... Read More
